Chenyi Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenyi Zhu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yang
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Changcheng Guo
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Chengqi Jin
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Jing Xu
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
18 shared publications - Ruiliang Wang
Shanghai Tenth People’s Hospital 1 Department of Urology Tongji University School of Medicine, Shanghai, China
18 shared publications - Tingting Zhao
School of Life Sciences and Technology, Tongji University, Shanghai, China
18 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on Tumor Tissue
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on Tumor Tissue
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical Data Correlated with Genomic Alterations
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical Data Correlated with Genomic Alterations
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Genomic landscape and concordance of alterations in tumor tissue and ctDNA. AR, androgen receptor; Doc, docetaxel; N/A, not applicable.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Genomic landscape and concordance of alterations in tumor tissue and ctDNA. AR, androgen receptor; Doc, docetaxel; N/A, not applicable.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Internal validation of the b.TRPC model and comparison with ctDNA%. A and B, ROC curves comparing the predictive performance of b.TRPC and ctDNA% for 0.5-, 1-, and 2-year CRPC-free survival. C and D, Calibration plots showing the agreement between predicted and observed survival probabilities for b.TRPC and ctDNA%. E, C-index values demonstrating the superior prognostic accuracy of b.TRPC compared with ctDNA%. F–H, DCA illustrating the net clinical benefit of b.TRPC across different time points. FPR, false positive rate; TPR, true positive rate.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Internal validation of the b.TRPC model and comparison with ctDNA%. A and B, ROC curves comparing the predictive performance of b.TRPC and ctDNA% for 0.5-, 1-, and 2-year CRPC-free survival. C and D, Calibration plots showing the agreement between predicted and observed survival probabilities for b.TRPC and ctDNA%. E, C-index values demonstrating the superior prognostic accuracy of b.TRPC compared with ctDNA%. F–H, DCA illustrating the net clinical benefit of b.TRPC across different time points. FPR, false positive rate; TPR, true positive rate.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Figure S1. Construction of the alternative genes signature for prognostic risk prediction.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Figure S1. Construction of the alternative genes signature for prognostic risk prediction.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
External validation of the b.TRPC model in an independent dataset. A and B, ROC curves assessing the predictive performance of b.TRPC for 0.5-, 1-, and 2-year CRPC-free survival in the external validation cohort. C and D, Calibration plots confirming the reliability of the b.TRPC model across all time points. E, Comparison of C-index values for b.TRPC and ctDNA% in the external dataset. F–H, DCA demonstrating the clinical utility of b.TRPC for risk stratification in an independent patient cohort. FPR, false positive rate; TPR, true positive rate.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
External validation of the b.TRPC model in an independent dataset. A and B, ROC curves assessing the predictive performance of b.TRPC for 0.5-, 1-, and 2-year CRPC-free survival in the external validation cohort. C and D, Calibration plots confirming the reliability of the b.TRPC model across all time points. E, Comparison of C-index values for b.TRPC and ctDNA% in the external dataset. F–H, DCA demonstrating the clinical utility of b.TRPC for risk stratification in an independent patient cohort. FPR, false positive rate; TPR, true positive rate.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical significance of b.TRPC in patients undergoing different therapeutic regimens. A, Kaplan–Meier curves of progression-free survival (PFS) in b.TRPC-positive vs. b.TRPC-negative patients receiving ADT monotherapy. B, PFS outcomes in b.TRPC-positive and b.TRPC-negative patients treated with doublet therapy. C, Kaplan–Meier analysis of PFS in b.TRPC-positive and b.TRPC-negative patients administered triplet therapy. Training set (top); validation set (bottom).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Clinical significance of b.TRPC in patients undergoing different therapeutic regimens. A, Kaplan–Meier curves of progression-free survival (PFS) in b.TRPC-positive vs. b.TRPC-negative patients receiving ADT monotherapy. B, PFS outcomes in b.TRPC-positive and b.TRPC-negative patients treated with doublet therapy. C, Kaplan–Meier analysis of PFS in b.TRPC-positive and b.TRPC-negative patients administered triplet therapy. Training set (top); validation set (bottom).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on ctDNA
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Multivariate Analysis of Prognostic Factors Based on ctDNA
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Figure S2. Nomogram for predicting progression-free survival (PFS) based on t.TRPC and disease volume score.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Figure S2. Nomogram for predicting progression-free survival (PFS) based on t.TRPC and disease volume score.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Genomic Alterations in Tumor Tissue and ctDNA
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
Genomic Alterations in Tumor Tissue and ctDNA